<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126076">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01920074</url>
  </required_header>
  <id_info>
    <org_study_id>APT-NIT_S-PRO-M_PEDKPK1_E</org_study_id>
    <nct_id>NCT01920074</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic,Safety and Exploratory Efficacy of RECTIV® in Adolescents With Chronic Anal Fissure</brief_title>
  <official_title>A Phase 4, Multiple-dose, Pharmacokinetic, Safety, and Exploratory Efficacy Study of Nitroglycerin Ointment 0.4% (RECTIV®) in Adolescents (Age ≥12 to &lt;17 Years) With Moderate to Severe Pain Due to Chronic Anal Fissure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aptalis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aptalis Pharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RECTIV® is an ointment containing 0.4% nitroglycerin (NTG) for the treatment of moderate to
      severe pain associated with chronic anal fissure approved in June 2011 by the US Food and
      Drug Administration (FDA) for adults. The purpose of this study is to assess the safety,
      pharmacokinetics, and exploratory efficacy of RECTIV® in adolescents
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter study conducted in up to 10 sites in the United States.
      A total of 13 pediatric male or female patients age ≥12 to &lt;17 years will be enrolled. The
      patients will administer a dose of Rectiv®  twice daily to characterize the safety,
      pharmacokinetics , and exploratory efficacy of Nitroglycerin Ointment 0.4% (RECTIV® )over 5
      days
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Noncompartmental pharmacokinetic analyses will be performed on the full pharmacokinetic curves for NTG and its metabolites (1,2 glyceryl dinitrate and 1,3 glyceryl dinitrate) on Day 5</measure>
    <time_frame>Day 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>The following PK parameters will be calculated as data permit:
Maximum observed concentration (Cmax)
Time of the maximum observed plasma concentration (Tmax)
Area under the concentration time curve from dosing up to the last quantifiable concentration (AUC0-last).
Area under the concentration time curve from dosing up to 480 minutes (AUC0-480)
The extrapolated area under the concentration time curve from dosing up to 12 hours (AUC0-12h) also will be calculated if quantifiable concentrations are observed during the entire dose interval.
Terminal elimination half-life (t1/2) On the basis of the results of the study, additional noncompartmental PK parameters may be calculated and reported.
In addition, a population PK model for NTG will be developed based on the PK data from Day 5.  By using this model, the following additional PK parameters may be reported:
Apparent volume of distribution (V/F)
Apparent clearance (CL/F)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Absolute change from baseline  in 24-hour average anal fissure pain scores assessed by the Wong-Baker FACES® and the Numerical Rating Scale for pain after each evening dose over days 1 through 4</measure>
    <time_frame>Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess the safety of Rectiv® in adolescents (age ≥12 to &lt;17 years)</measure>
    <time_frame>Screening through the completion of study participation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety and tolerability are assessed through AEs, clinical laboratory test results (hematology, serum biochemistry, and urinalysis), vital sign measurements (heart rate, supine and orthostatic blood pressure, oral temperature, and respiratory rate), 12-lead ECG results, anal area assessment, physical examination findings (including body weight), and concomitant medications (including the use of rescue acetaminophen for headaches).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">13</enrollment>
  <condition>Anal Fissure</condition>
  <arm_group>
    <arm_group_label>Rectiv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin Ointment 0.4%</intervention_name>
    <arm_group_label>Rectiv</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female ≥12 and &lt;17 years of age

          -  At least 1 anal fissure for a minimum of 3 weeks in duration

          -  Anal fissure pain experienced over the last 24 hours at Screening and before
             enrollment

          -  Patient (and parent or caregiver as appropriate) has provided written  informed
             consent

        Key Exclusion Criteria:

          -  Current diagnosis of hemorrhoids

          -  Hypersensitivity, allergy, or contraindication to nitroglycerin

          -  History of hypertension and/or cardiovascular disease

          -  History or current diagnosis of inflammatory bowel disease

          -  History or current diagnosis of fistula(e)-in-ano or an anal abscess

          -  Fibrotic anal stenosis

          -  Previous anal surgery

          -  Diagnosis of cancer

          -  History of migraine or chronic headaches requiring treatment with analgesics

          -  Pregnant or lactating female patients

          -  Weight &lt;36 kg
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gina Eagle, MD</last_name>
    <role>Study Director</role>
    <affiliation>Aptalis Pharma, Bridgewater, NJ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Hyman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital, New Orleans, LA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carla M. Charles, MBS</last_name>
    <phone>908-927-9600</phone>
    <phone_ext>4075</phone_ext>
    <email>ccharles@aptalispharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rula Harb, MD</last_name>
      <phone>323-361-4956</phone>
      <email>rharb@chla.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tatiana Hernandez</last_name>
      <phone>323.361.8631</phone>
      <email>thernandez@chla.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hillel Naon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rula Harb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael A Garcia, MD</last_name>
      <phone>786-360-4423</phone>
      <email>advancemrc@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ana Acosta</last_name>
      <phone>786-360-4423</phone>
      <email>advancemrc@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rafael A Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aldo V Fonticiella, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Devendra Mehta, MD</last_name>
      <phone>321-841-6350</phone>
      <email>devendra.mehta@orlandohealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Logie</last_name>
      <phone>321-841-6350</phone>
      <email>sarah.logie@orlandohealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Devendra Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffery Bornstien, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reinaldo Figueroa-Colon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Hyman, MD</last_name>
      <phone>504-896-9534</phone>
      <email>phyman@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Hyman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sealy Urgent Care Center and Medical Clinic</name>
      <address>
        <city>Sealy</city>
        <state>Texas</state>
        <zip>77474</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Demirbag S, Tander B, Atabek C, Surer I, Oztürk H, Cetinkursun S. Long-term results of topical glyceryl trinitrate ointment in children with anal fissure. Ann Trop Paediatr. 2005 Jun;25(2):135-7.</citation>
    <PMID>15949202</PMID>
  </results_reference>
  <results_reference>
    <citation>Kenny SE, Irvine T, Driver CP, Nunn AT, Losty PD, Jones MO, Turnock RR, Lamont GL, Lloyd DA. Double blind randomised controlled trial of topical glyceryl trinitrate in anal fissure. Arch Dis Child. 2001 Nov;85(5):404-7.</citation>
    <PMID>11668104</PMID>
  </results_reference>
  <results_reference>
    <citation>Schiano di Visconte M, Di Bella R, Munegato G. Randomized, prospective trial comparing 0.25 percent glycerin trinitrate ointment and anal cryothermal dilators only with 0.25 percent glycerin trinitrate ointment and only with anal cryothermal dilators in the treatment of chronic anal fissure: a two-year follow-up. Dis Colon Rectum. 2006 Dec;49(12):1822-30.</citation>
    <PMID>17096178</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 16, 2013</lastchanged_date>
  <firstreceived_date>August 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anal Fissure</keyword>
  <keyword>Nitroglycerin</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>RECTIV®</keyword>
  <keyword>Pediatric Research Equity Act</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fissure in Ano</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
